Bellevue reports 10.6 percent stake in Yarrow Bioscience stock

Published on 10/16/2026 at 03:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bellevue disclosed 1,000,000 shares on October 7, 2026. Yarrow Bioscience stock had 9,437,693 shares outstanding after the offering.

Ownership and financing milestones

Bellevue reported 1,000,000 shares, equal to 10.6 percent, on October 7, 2026.
Second-quarter revenue reached USD 0.10 million, while earnings per share were negative USD 3.51.
Yarrow Bioscience's next earnings date is November 5, 2026.

YARW, US92941V4077, Illustration mit AI erstellt.

Yarrow Bioscience (ISIN US92941V4077) gained a new large shareholder disclosure when Bellevue reported 1,000,000 shares, equal to 10.6 percent of the company, on October 7, 2026. The filing followed a September capital raise that expanded the biotechnology company's share base.

Three ownership milestones

The latest filing completed a sequence of financing and ownership events. On August 13, 2026, Yarrow reported second-quarter revenue of USD 0.10 million and a loss of USD 3.51 per share, according to MarketBeat. On September 14, 2026, the company closed a USD 172.5 million underwritten public offering, as reported by StockTitan. Bellevue's October 7 filing was the third dated milestone, assigning 1,000,000 shares to the investment group.

What does the stake change?

The filing gives Bellevue a 10.6 percent position based on 9,437,693 shares outstanding after the offering. That ownership level makes the investor a material shareholder as Yarrow advances its clinical-stage biotechnology program. The company is developing YB-101 for autoimmune thyroid diseases, including Graves' disease and thyroid eye disease.

Results date sets the next marker

Yarrow's second-quarter figures show a business still centered on development spending rather than product revenue. Revenue of USD 0.10 million was below the USD 0.20 million consensus cited by MarketBeat, while the reported loss of USD 3.51 per share missed the USD 0.18 consensus loss. The next earnings date is November 5, 2026, according to Quanteia.

Market value and listing

Yarrow Bioscience's market capitalization stood at USD 186.1 million on October 15, 2026. MarketWatch identifies the company as a Nasdaq issuer under ticker YARW, keeping the ownership filing and November reporting date as the clearest near-term reference points for the stock.